Unknown

Dataset Information

0

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).


ABSTRACT: INTRODUCTION:No study has compared the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL). METHODS:We enrolled 253 drug-naïve Japanese patients with type 2 diabetes mellitus (T2DM), randomly assigned them into a dapagliflozin (SGLT2i) group or DPP4i group in approximately 1:1 ratio, and monitored them for 24 weeks. The primary endpoint was the proportion of subjects indicating improvement in the "overall quality of life" domain of SHIELD-WQ-9 at week 24. Secondary endpoints included other domains of SHIELD-WQ-9, DTR-QOL, EQ-5D-5L, medication preference, medication adherence, diet therapy adherence, body weight, body mass index (BMI), abdominal circumference, HbA1c, and frequency of adverse events. RESULTS:The proportion of subjects indicating improvement in the "overall quality of life" domain of SHIELD-WQ-9 at week 24 was higher in the dapagliflozin group (28.4%) than in the DPP4i group (18.6%) (p?=?0.08). The proportion of subjects indicating improvement in the "physical health" domain of SHIELD-WQ-9 at week 24 was significantly higher in the dapagliflozin group (42.2%) than in the DPP4i group (23.7%) (p?=?0.004). Total scores and domain 1 scores of DTR-QOL showed greater improvement in the dapagliflozin group (14.3?±?15.6 and 15.5?±?20.8, respectively) than in the DPP4i group (10.2?±?15.6 and 10.3?±?19.5, respectively) (both p?=?0.05). EQ-5D-5L scores had significantly improved in the DPP4i group (0.023?±?0.088) (p?=?0.005); the intergroup difference was not significant (p?=?0.14). Body weight (p?

SUBMITTER: Ishii H 

PROVIDER: S-EPMC7644655 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quality-of-Life Comparison of Dapagliflozin Versus Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial (J-BOND Study).

Ishii Hitoshi H   Nakajima Hiroki H   Kamei Nozomu N   Niiya Tetsuji T   Hiyoshi Toru T   Hiramori Yuko Y   Ohtsu Shigeyuki S   Noto Takashi T   Shimono Dai D  

Diabetes therapy : research, treatment and education of diabetes and related disorders 20201015 12


<h4>Introduction</h4>No study has compared the effects of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and dipeptidyl peptidase 4 inhibitors (DPP4is) on patients' quality-of-life (QOL).<h4>Methods</h4>We enrolled 253 drug-naïve Japanese patients with type 2 diabetes mellitus (T2DM), randomly assigned them into a dapagliflozin (SGLT2i) group or DPP4i group in approximately 1:1 ratio, and monitored them for 24 weeks. The primary endpoint was the proportion of subjects indicating improvement  ...[more]

Similar Datasets

| S-EPMC8159755 | biostudies-literature
| S-EPMC8792822 | biostudies-literature
| S-EPMC10712048 | biostudies-literature
| S-EPMC8390252 | biostudies-literature
| S-EPMC3898344 | biostudies-literature
| S-EPMC9331841 | biostudies-literature
| S-EPMC7648323 | biostudies-literature
| S-EPMC7954778 | biostudies-literature
| S-EPMC3654348 | biostudies-other